Publication
Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerBasal Cell Carcinomacivic_curation1.00
- drugArsenic Trioxidecivic_curation1.00
- drugPSIcivic_curation1.00
- drugVismodegibcivic_curation1.00
- geneSMOcivic_curation1.00
- variantSMO D473Hcivic_curation1.00
- variantSMO L412Fcivic_curation1.00
- variantSMO Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (10)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25759020
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| SMO D473G1 | ||||||||
| Vismodegib | Basal Cell Carcinoma | Predictive | C | Supports Resistance | — | submitted | EID4634In 3 basal cell carcinoma (BCC) patients harboring a SMO D473G mutation, SMO D473G mutation was reported to be resistant to vismodegib treatment. In an in vitro study, mouse embryonic fibroblasts (ME… (full text at CIViC) PMID 25759020 · Atwood et al., 2015 · Open in CIViC | civic |
| SMO D473H1 | ||||||||
| Vismodegib | Basal Cell Carcinoma | Predictive | D | Supports Resistance | 3 | accepted | EID755D473 mutations were identified in 5/30 resistant basal cell carcinomas. Crystal structure indicated this mutation interacts with a water molecule in the ligand binding pocket, putatively altering its … (full text at CIViC) PMID 25759020 · Atwood et al., 2015 · Open in CIViC | civic |
| SMO L412F1 | ||||||||
| Vismodegib | Basal Cell Carcinoma | Predictive | D | Supports Resistance | — | accepted | EID4653In an in vitro study, mouse embryonic fibroblasts (MEFs), null for the Smo mouse gene expressing SMO L412F mutation, demonstrated resistance to vismodegib treatment (IC50: >320 nmol/L vs. 8.23 nmol/L)… (full text at CIViC) PMID 25759020 · Atwood et al., 2015 · Open in CIViC | civic |
| SMO Mutation2 | ||||||||
| Arsenic Trioxide + PSISubstitutes | Basal Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID747Basal cell carcinomas with ligand-binding pocket or constitutively active mutations in the SMO gene were sensitive to inhibition of downstream hedgehog signaling with PSI (aPKC-ι/λ/GLI inhibitor) or a… (full text at CIViC) PMID 25759020 · Atwood et al., 2015 · Open in CIViC | civic |
| Vismodegib | Basal Cell Carcinoma | Predictive | B | Supports Resistance | 4 | accepted | EID746In basal cell carcinoma, H231R, D473G, W281C and Q477E mutations conferred resistance to SMO-inhibitor vismodegib. SMO mutations were identified in 22 of 44 resistant basal cell carcinomas in 15 patie… (full text at CIViC) PMID 25759020 · Atwood et al., 2015 · Open in CIViC | civic |
| SMO Q477E1 | ||||||||
| Vismodegib | Basal Cell Carcinoma | Predictive | D | Supports Resistance | — | submitted | EID4639In an in vitro study, mouse embryonic fibroblasts (MEFs) null for the Smo mouse gene, expressing SMO Q477E mutation, demonstrated resistance to vismodegib treatment (IC50: >320 nmol/L vs. 8.23 nmol/L)… (full text at CIViC) PMID 25759020 · Atwood et al., 2015 · Open in CIViC | civic |
| SMO S278I1 | ||||||||
| Vismodegib | Basal Cell Carcinoma | Predictive | C | Supports Resistance | — | submitted | EID4636In a retrospective study of 15 vismodegib-resistant basal cell carcinoma (BCC) patients, a BCC patient harboring SMO S278I mutation was reported to be resistant to vismodegib monotherapy. PMID 25759020 · Atwood et al., 2015 · Open in CIViC | civic |
| SMO V321M1 | ||||||||
| Vismodegib | Basal Cell Carcinoma | Predictive | D | Supports Resistance | — | submitted | EID4661In an in vitro study, mouse embryonic fibroblasts (MEFs), null for the Smo mouse gene expressing SMO V321M mutation, demonstrated resistance to vismodegib treatment (IC50: >320 nmol/L vs. 8.23 nmol/L)… (full text at CIViC) PMID 25759020 · Atwood et al., 2015 · Open in CIViC | civic |
| SMO W281C1 | ||||||||
| Vismodegib | Basal Cell Carcinoma | Predictive | D | Supports Resistance | — | submitted | EID4637In an in vitro study, mouse embryonic fibroblasts (MEFs) null for the Smo mouse gene, expressing SMO W281C mutation, demonstrated resistance to vismodegib treatment (IC50: >320 nmol/L vs. 8.23 nmol/L)… (full text at CIViC) PMID 25759020 · Atwood et al., 2015 · Open in CIViC | civic |
| SMO W535L1 | ||||||||
| Vismodegib | Basal Cell Carcinoma | Predictive | C | Supports Resistance | — | submitted | EID3735In 5 basal cell carcinoma patients harboring a SMO W535L mutation, SMO W535L was reported to be resistant to vismodegib treatment. In an in vitro study, mouse embryonic fibroblasts (MEFs) null for the… (full text at CIViC) PMID 25759020 · Atwood et al., 2015 · Open in CIViC | civic |